Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Payables: 2020-2024

Historic Payables for Mirum Pharmaceuticals (MIRM) over the last 5 years, with Dec 2024 value amounting to $14.6 million.

  • Mirum Pharmaceuticals' Payables rose 27.47% to $12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.1 million, marking a year-over-year increase of 31.07%. This contributed to the annual value of $14.6 million for FY2024, which is 97.11% up from last year.
  • Latest data reveals that Mirum Pharmaceuticals reported Payables of $14.6 million as of FY2024, which was up 97.11% from $7.4 million recorded in FY2023.
  • In the past 5 years, Mirum Pharmaceuticals' Payables ranged from a high of $14.6 million in FY2024 and a low of $3.2 million during FY2020.
  • Moreover, its 3-year median value for Payables was $8.7 million (2022), whereas its average is $10.2 million.
  • As far as peak fluctuations go, Mirum Pharmaceuticals' Payables spiked by 190.89% in 2021, and later decreased by 14.66% in 2023.
  • Over the past 5 years, Mirum Pharmaceuticals' Payables (Yearly) stood at $3.2 million in 2020, then spiked by 190.89% to $9.2 million in 2021, then fell by 5.19% to $8.7 million in 2022, then dropped by 14.66% to $7.4 million in 2023, then skyrocketed by 97.11% to $14.6 million in 2024.